Catalyst Pharmaceuticals, Inc.

Valuation Analysis

About the Company

Catalyst Pharmaceuticals, Inc. en bref

Catalyst Pharmaceuticals, Inc. (CPRX) is currently trading at 27,38 € with a market capitalization of 3,4 Md €. The trailing P/E ratio stands at 18.14x, with a forward P/E of 9.86x. The 52-week range spans from 16,62 € to 28,41 €; the current price is 3.6% below the yearly high. Year-over-year revenue growth stands at +5.6%. The net profit margin stands at 37.08%.

💰 Dividende

Catalyst Pharmaceuticals, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

3 analystes évaluent Catalyst Pharmaceuticals, Inc. (CPRX) au consensus : Conserver. L'objectif de cours moyen est de 27,64 €, soit un potentiel de +0.91% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 27,49 € à 27,93 €.

Catalyst Pharmaceuticals, Inc. : la thèse d'investissement en détail

Catalyst Pharmaceuticals, Inc. (CPRX) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

With a gross margin near 84.04%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Free cash flow is positive and net margins stand at 37.08%, meaning reported earnings translate into real cash that can fund buybacks, dividends or strategic acquisitions.

À surveiller

• The forward P/E of 9.86x is meaningfully below the trailing 18.14x — analysts expect earnings to step up; the next earnings release is the test.
• The share is trading at 91.3% of its 52-week range — a break above the recent high opens technical upside, a failure here often invites profit-taking.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Profil de risque

The data points to relatively defensive market behavior, elevated short interest (8.29%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Catalyst Pharmaceuticals, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.